Overview

A Study to Assess the Safety and Tolerability of Single Doses of AZD4076 in Healthy Male Subjects

Status:
Active, not recruiting
Trial end date:
2022-02-22
Target enrollment:
Participant gender:
Summary
This is a first-in-human (FIH) study designed to evaluate the safety, tolerability, and pharmacokinetics (PK) of AZD4076 tetracosasodium in healthy male subjects at increasing single doses.
Phase:
Phase 1
Details
Lead Sponsor:
AstraZeneca